{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"19"},{"groupId":"OG007","value":"764"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"19"},{"groupId":"OG007","value":"764"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"6"}],"units":"Participants"}],"groups":[{"description":"Participants received Selpercatinib 20 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG000","title":"Phase 1: 20 mg Selpercatinib QD"},{"description":"Participants received Selpercatinib 20 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG001","title":"Phase 1: 20 mg Selpercatinib BID"},{"description":"Participants received Selpercatinib 40 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG002","title":"Phase 1: 40 mg Selpercatinib BID"},{"description":"Participants received Selpercatinib 60 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG003","title":"Phase 1: 60 mg Selpercatinib BID"},{"description":"Participants received Selpercatinib 160 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG004","title":"Phase 1: 160 mg Selpercatinib QD"},{"description":"Participants received Selpercatinib 80 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG005","title":"Phase 1: 80 mg Selpercatinib BID"},{"description":"Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG006","title":"Phase 1: 120 mg Selpercatinib BID"},{"description":"Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG007","title":"Phase 1: 160 mg Selpercatinib BID"},{"description":"Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG008","title":"Phase 1: 200 mg Selpercatinib BID"},{"description":"Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG009","title":"Phase 1: 240 mg Selpercatinib BID"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Participants who received at least 1 or more doses of selpercatinib and had evaluable data for this outcome.","reportingStatus":"POSTED","timeFrame":"Up to 28 days","title":"Phase 1: Number of Participants With an Abnormal Laboratory Values","type":"SECONDARY","unitOfMeasure":"Participants"}